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Abstract
Quality of life in general and sexual functioning in particular have become very important in cancer patients. Due to modern surgical
techniques, improved quality of drugs for chemotherapy and very modern radiation techniques, more patients can be successfully treated
without largely compromising sexual functioning. One can assume that because of the life-threatening nature of cancer, sexual activity is not
important to patients and their partners, but this is not true. Prostate cancer has become the most common non-skin malignant neoplasm in
older men in Western countries.
In this paper, we discuss the various methods used to evaluate erectile and sexual dysfunction and the definition of potency. Data on the
etiology of erectile dysfunction after external-beam radiotherapy for prostate cancer is reviewed, and the literature is been summarized. Patients
should be offered sexual counseling and informed about the availability of effective treatments for erectile dysfunction, such as sildenafil,
∗ Tel.: +31 10 43 91 421; fax: +31 10 43 91 013.
E-mail address: L.Incrocci@erasmusmc.nl.
1040-8428/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
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intracavernosal injection, and vacuum devices. Cancer affects quality of life and sexual function. The challenge for oncologists is to address
this with compassion.
© 2005 Elsevier Ireland Ltd. All rights reserved.
Keywords: Prostate cancer; Radiotherapy; Radiation; Erectile (dys)function; Sexual (dys)function
1. Introduction
Despite the decrease in overall cancer incidence and mor-
tality rates in developed countries since the early 1990s,
cancer remains a major public health problem. Among men,
the most common cancer affects the prostate and occurs more
often in the older population [1]. In recent years, the number
of patients diagnosed with prostate cancer (PC) has increased
dramatically because of the widespread use of prostate spe-
cific antigen testing and the possibility for cure of early
disease. Standard treatments for PC are radical prostatec-
tomy, external-beam radiotherapy (EBRT), brachytherapy, or
observation. The choice of treatment is usually determined by
tumor staging, patient’s age and comorbidity, urologist’s and
patient’s preferences. Sexual dysfunction is one of the more
common consequences of cancer treatment [2]. Patient’s
quality of life, including sexual functioning, should play a
more significant role in decision making about treatment type.
Men may remain interested in sex and eroticism well into
old age [3]. Men are less likely than women to seek profes-
sional help for mental and physical health problems. Addis
and Mahalik hypothesized that cultural norms of masculinity
conflict with help-seeking behavior [4]. Erectile dysfunction
(ED) is a medical problem often crucial to men’s self-esteem.
In the 1980s and 1990s, penile prostheses and penile injec-
tions created a market for male sexual dysfunction. With the
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With a few exceptions [2,6,7,15,16], the entire questionnaire
used was not included in the paper, and only selected ques-
tions were listed [5,8,12,17–21]. In many of the older papers,
mainly from the 1970s and the 1980s, only rates of potency or
impotence were mentioned [22–35], without reference to the
methodology used. Seldom was a complete questionnaire on
various aspects of sexuality used [17–19,36,37]. Validation
of the instrument used was seldomly reported [5,7,10,13,38].
More recently an international questionnaire, the Interna-
tional Index of Erectile Function (IIEF) has been introduced
[39]. The IIEF has been translated and validated in many
countries and offers the possibility to make comparisons
between different studies. Though, it has not been specifi-
cally developed for cancer patients.
2.1. Summary
Internationally validated questionnaires are available to
evaluate sexual functioning. These should always be used, to
ensure comparisons between different studies.
3. Definition of potency
Another significant feature of literature on ED after radia-
tion for PC is the definitions of potency and impotence used.
A clear definition is mandatory in order to make meaningful
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pntroduction of sildenafil (Viagra®) in 1998, media attention
o ED has made sexual problems more normative and has
ncreased acceptance of help-seeking [4].
The purpose of this paper is to present an overview of
he peer-reviewed articles dealing with ED after EBRT. Arti-
les dealing with PC-patients with metastatic disease, or on
ormone therapy, are not included in this review. Firstly, the
arious methods used to evaluate and define ED will be dis-
ussed. Then, the etiology of ED after EBRT will be reviewed.
he literature on the incidence of erectile and other sexual
ysfunctions after EBRT will be summarized. Finally, the
herapy of post-radiation ED and prevention possibilities will
e discussed.
. Methods of evaluating erectile dysfunction
The most practical and quickest way to evaluate ED is
y using a questionnaire. Different questionnaires have been
sed in the published literature. Questions on sexual func-
ioning were quite often limited to two to six items, and were
ncorporated into a more general questionnaire on toxicity
f radiation treatment, or quality of life in general [2,5–14].omparisons of the different studies. The National Institutes
f Health (NIH) Consensus on ED defined impotence as: the
onsistent inability to attain and maintain a penile erection
ufficient to permit satisfactory sexual intercourse [40]. One
ould argue that such a definition is strictly relevant in the
resence of a willing partner. As such, use of the general
erm sexual activity, i.e. intercourse or masturbation, would
e more appropriate. Rigidity of erections, presence of spon-
aneous daytime erections or morning/night erections (quite
elevant in the differentiation between organic and psycho-
ogical etiology) are also important issues. It is also necessary
o differentiate between ED and not being sexually active,
ften due to reasons not correlated to erectile insufficiency,
uch as absence of a willing partner or the lack of interest in
ex. Psychological factors in irradiated patients may play a
ole in post-radiation ED and have to be kept in mind.
In most published studies, authors referred to the
eneral terms potency or impotence without giving a
roper operational definition [5,7,8,10,15,20,33]. In some
rticles, a detailed definition of potency was provided
2,7,12,13,16,19,24,35,37,41], though this was often not
omparable: Is a good erection one that is assessed by the
atient, or by his physician? Is it necessary to use a compli-
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cated definition, or is the NIH definition sufficient? Is only
the presence of an erection important, or do we need to know
the duration and the rigidity of these erections which allows
sexual activity? Such questions remain unanswered in the
radiotherapy literature.
3.1. Summary
In most of the published studies, a definition of potency is
lacking. The definition advocated by the NIH should be used,
also to allow comparisons of data among different studies.
4. Etiology of post-radiation erectile dysfunction
See Fig. 1 for a schematic of the male genitalia.
Goldstein et al. [42] performed a detailed study on 23
patients treated with radiotherapy for PC in order to under-
stand the etiology of radiation-induced impotence. Noc-
turnal penile tumescence testing, bulbo-cavernous reflex
latency, perineal electromiography, penile Doppler ultra-
sonography, and endocrine screening of the hypothalamic-
pituitary-gonadal axis were performed. Subjects were con-
sidered potent if they could develop an erection sufficiently
rigid for vaginal penetration and sustain it until ejaculation.
A
r
m
n
the patients. A selective pudendal arteriography performed
in two subjects revealed occlusive vascular disease within
the pelvic radiation field. The authors concluded that post-
radiation ED was due to vascular damage [42]. One year
later, a study by Mittal [43] on penile circulation measured
with Penile Brachial Index and Penile Flow Index in six
patients did not show any statistically significant differences
between pre- and post-radiation values. Mittal [43] concluded
that penile circulation was not abnormal after radiation and
that the etiology of ED was a more complex mechanism
not directly attributable to vascular damage as previously
suggested by Goldstein et al. [42]. More recently, Zelefsky
and Eid [44] evaluated 98 patients who became impotent
after EBRT or prostatectomy, and confirmed the findings by
Goldstein et al. [42]. Median time from surgery and radia-
tion to evaluation was 11 and 14 months, respectively. The
penis was scanned with Duplex ultrasound before, and after,
an intracavernosal injection of prostaglandin. Among EBRT
patients, 32% had cavernosal dysfunction (abnormal caver-
nosal distensibility with a normal penile peak blood flow) and
63% arteriogenic dysfunction (peak penile blood flow rates
less than 25 cm/s). Neurogenic dysfunction was found in 3%
of the EBRT patients. Comorbidity, hormonal manipulation,
smoking and age did not influence the type of dysfunction
observed. The authors concluded, as Goldstein et al. [42], that
the predominant etiology of radiation-induced impotence was
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tll the 15 patients who met the criteria for potency before
adiation complained of a worsening in erectile function 14
onths after radiotherapy. Neurological examinations were
ormal, while penile Doppler evaluation was abnormal in allFig. 1. Schematic of the male genitalia and innervation. trteriogenic. The Mittal’s study [43] was not consistent with
hese two other studies [42,44]. Different reasons can explain
his: the evaluation of erectile function at 6–9 months after
adiation is too early to detect radiation damage to vessels;
he tests used are obsolete, and not reliable; the number of
atients evaluated is too small (only six).
Very recently Fisch et al. [45] evaluated the effect of the
BRT dose to the bulb of the penis on erectile function in 21
atients, at 2 years after treatment. A strong dose–volume
elationship with the likelihood of remaining potent after
BRT was observed. Patients who received 70 Gray or more
o 70% of the bulb of the penis appeared to be at very high
isk of developing radiation-induced ED. See Fig. 2 for the
elation of the penile bodies with the radiation fields. Selek
t al. [46] could not find any correlation between the dose
nd volume of radiation to proximal penile structures and
he development of ED after EBRT. The authors reported
n 28 patients treated with 78 Gy and potent prior to radi-
tion. At 2 years follow-up 10 patients reported ED. There
as no statistically significant difference in the radiation dose
o the corpus spongiosum, corpora cavernosa, and crura and
otal penile structure between potent and non-potent patients
46]. A fused computer tomography (CT)/magnetic reso-
ance imaging (MRI) simulation study before treatment in
9 intensity-modulated radiation therapy (IMRT) patients
howed that the dose to the penile bulb and corporal bod-
es is low with IMRT. MRI appeared to be superior to CT for
he imaging of erectile tissues [47]. Although these data have
o be confirmed by larger studies, it seems warranted to limit
he dose to the bulb of the penis to prevent post-radiation ED
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Fig. 2. Example of an anterior–posterior conformal radiation field for
prostate cancer. Relation of the penile bodies and radiation field.
[45]. However, there is no data on PC control, when the dose
to the bulb of the penis is limited.
4.1. Summary
Although very few studies have been performed on the
etiology of post-radiation ED, the most likely mechanism
seems to be radiation damage to the pelvic vasculature and
penile bodies.
5. Incidence of ED after external-beam radiotherapy
5.1. Studies published in the 1970s
Papers from the 1970s dealt with the introduction of EBRT
for PC in the pre-PSA era. Until then, surgery was the main
stay of treatment as most urologists considered PC to be
a relatively radio-resistant tumor, an idea derived from the
poor results obtained using conventional orthovoltage ther-
apy. Although studies in the 1970s reported on treatment
outcome, and urinary and bowel sequelae, mention of sexual
potency or impotence was also frequently made (see Table 1).
ED incidence was reported in up to 41% [22,23,25–27]. In
most cases methods of evaluation, definition of potency, indi-
cation of a trans-urethral resection of the prostate (TURP)
prior to EBRT, comorbidity and the time of assessment of
ED were not reported. The percentage of patients who were
potent before EBRT was often not provided. Consequently,
the percentage of patients who became impotent after treat-
ment may have been overestimated.
5.2. Studies published in the 1980s
In the 1980s, EBRT was delivered using megavolt ener-
gies. Papers from the 1980s did not differ much from the
1970s (see Table 1). Radiation-induced sexual dysfunction
was mentioned in most studies with percentages from 11 to
73% [24,28,29,31]. Only two papers [30,35] reported more
extensively on post-radiation sexual dysfunction, including
libido, frequency of coitus, and ejaculation. Men who were
sexually active before treatment had a good chance of retain-
ing potency 8–12 months after EBRT [30], and, for the first
t
b
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Table 1
Erectile dysfunction after external-beam radiotherapy (EBRT) for prostate cancer:
Authors Patients, n Mean agea years
(range)
Patients potent p
(%)
Ray et al. [22] 310 63 (39–89) 96 (31)
Bagshaw et al. [23] 430 59 (n.a.) 110 (26)
McGowan [25] 107 64 (50–79) n.a.
Perez et al. [26] 112 n.a. (40–81) n.a.
Taylor [27] 278 n.a. 108 (39)
F
A
B
B
V
S
norman et al. [28] 240 68 (52–86) 105 (44)
sbell et al. [29] 445 68 (n.a.) n.a.
agshaw et al. [24] 914 63 (35–86) 434 (47)
anker [30] 85 n.a. 26 (30)
an Heeringen et al. [36] 18 71 (60–82) 11 (61)
hipley et al. [31] 121 68 (n.a.) 54 (45)
.a., data not available.
a Mean age for entire group.
b Median.ime, the need for adequate information on sexual functioning
efore treatment was emphasized [36].
.3. Retrospective studies published in the 1990s
This period was characterized by PSA testing, and
he widespread use of EBRT. More specifically, three-
imensional conformal techniques (3DCRT), with the use of
ore fields, and shaped/customized blocks, a computer plan-
ing system and three-dimensional treatment plans resulted
n smaller treatment volumes. A common aspect of the
eported papers was the use of retrospective assessments
recall bias) or the use of medical chart records (no stan-
studies from the 1970s and the 1980s
rior to EBRT, n Mean follow-up months
(range)
ED, n (%)
n.a 30 (29/96) at 15 months
n.a. 41 (65/110) at 15 months
n.a. (24–65) 6 (7/107)
n.a. (12–60) 13 (15/112)
n.a. 22 (24/108)
40b (12–108) 43 (45/105)
84b (n.a.) 11–53 (n.a.)
up to 180 14 (n.a.) at 15 months
n.a. (8–12) 73 (19/26)
20 (4–45) 27 (3/11)
n.a. (60–114) 37 (20/54) at >36 months
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Table 2
Erectile dysfunction after external-beam radiotherapy (EBRT) for prostate cancer: retrospective studies from the 1990s
Authors Patients, n Mean agea years
(range)
Patients potent prior to EBRT, n
(%)
Mean follow-up months
(range)
ED, n (%)
Mameghan et al. [32] 218 67b (45–87) 42 (19) 55 (n.a.) 45 (19/42) at 24 months
Helgason et al. [18] 53 70 (53–80) 33 (66) n.a. (18–24) 50 (26/53)
Roach et al. [19] 124 72b (48–87) 60 (48) 21b (7–40) 38 (23/60)
Crook et al. [15] 192 70 (49–87) 158 (82) 33 (12–72) 35 (55/158)
Fransson and Widmark [7] 199 71b (51–86) n.a. 48 (24–56) 56 (n.a.)
Mantz et al. [34] 114 68 (52–85) n.a. 18 (n.a.) 2 (n.a.) at 1 month
8 (n.a.) at 12 months
25 (n.a.) at 24 months
34 (n.a.) at 36 months
Fossa˚ et al. [20] 114 69 (n.a.) 22 (19) n.a. 61 (13/22)
Nguyen et al. [11] 101 n.a. 81 (80) >24 49 (40/81)
Zelefsky et al. [35] 743 69b (51–84) 544 (73) 42b (18–109) 39 (211/544)
Wilder et al. [41] 51 68b (n.a.) 35 (69) 15b (n.a.) 0 at 12 months
17 (9/51) at 24 months
37 (19/51) at 36 months
Hamilton et al. [13] 457 n.a. 251 (55) n.a. 58 (n.a.) at 12 months
68 (n.a.) at 24 months
n.a., data not available.
a Mean age for entire group.
b Median.
dardized methods). The time at which sexual function was
evaluated was often not indicated. As time since radiother-
apy is important [7,13,34,35,41], it is mandatory to mention
it before proper comparisons of percentages of ED between
different studies can be made. Furthermore, comorbidity, age,
and pre-EBRT TURP were seldom mentioned. Cardiovascu-
lar disease, diabetes or impaired potency prior to EBRT were
often correlated with a higher incidence of ED post-treatment
in one study [34], but the contrary view was reported by
other authors [19,35,37,41]. Percentages of ED varied from
0 to 61% [7,11,13,15,18–20,32,34,41]. See Table 2 for an
overview. Lack of erections was reported in 56% of the EBRT
patients and in 12% in age-matched controls, more obviously
in men younger than 70 years [7]. Volume of tissue irradi-
ated did not influence sexual complications [7,11]. Patients
who were potent before EBRT, and who received a dose of
76 Gray or greater, had an impotence percentage of 68%
at 5 years versus 52% for those treated to 70 Gray or less
(p < 0.001) [35]. This is the first report to document a higher
incidence of ED with dose escalation after 3DCRT. Further-
more, neo-adjuvant androgen deprivation, TURP, diabetes,
age, and tumor stage were not significantly correlated to ED
rates [35].
5.4. Prospective studies published in the 1990s
A few studies from the 1990s (see Table 3) dealt specif-
ically with sexual functioning after EBRT and evaluated
patients prospectively. Such methodology is the only cor-
rect way to avoid recall bias of pre-treatment potency and
incomplete medical charts. Percentages of ED varied from 7
to 72% [8,9,16,17,33,37]. Radiation field size and technique
seemed to influence sexual function at 3 and 12 months after
EBRT, though this was not statistically significant [8].
Table 3
Erectile dysfunction after external-beam radiotherapy (EBRT) for prostate cancer: prospective studies from the 1990s
Authors Patients, n Mean agea years
(range)
Patients potent prior to EBRT n
(%)
Mean follow-up months
(range)
ED, n (%)
Zinreich et al. [17] 27 68 (52–80) 10 (37) n.a. 20 (2/10) at 12 months
Pilepich et al. [33] 230 71b (49–84) 102 (44) 54b (n.a.) 72 (74/102)
Beckendorf et al. [37] 67 68 (54–84) 40 (60) n.a. (8–12) 33 (13/40)
Beard et al. [8] 121 n.a. 69 (57) n.a. 57 (39/69) at 3 months
B
T
norghede and Hedelin [9] 184 67 (46–83) 134 (73)
urner et al. [16] 290 69 (44–82) 182 (63)
.a., data not available.
a Mean age for entire group.
b Median.64 (44/69) at 12 months
46 (24–96) 7 (9/134)
23b (n.a.) 38 (56/146) at 12 months
59 (40/68) at 36 months
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5.5. Summary
In the 1970s, studies reported on treatment outcome and
only incidentally on ED. The 1980s were characterized by
more focus on ED, although only two papers extensively
reported on post-radiation sexual dysfunction. Only in the
1990s a particular interest in post-radiation ED was shown.
Only studies that prospectively evaluated erectile function-
ing, using validated questionnaires and using a proper def-
inition of potency are useful to draw conclusions on the
incidence of post-radiation ED. In general, this reaches about
60–70% in prospective studies. Time elapsed since radia-
tion is important: prospective studies show an increase of ED
between 1 and 2 years after radiotherapy, but it does not seem
to change after 3 years.
6. Ejaculatory and other sexual dysfunctions
A deterioration of sexual activity has been associated
with the severity of ejaculatory dysfunction, particularly a
decrease in volume or an absence of semen [48]. After
EBRT, a lack of ejaculation was reported in 2–56% of
patients [6,18,25]. Dissatisfaction with sex life was reported
in 25–60% [49,50], decreased libido in 8–53% [36,37,50],
and decreased sexual desire in 12–58% [18,51]. One study
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faction and frequency of intercourse after receiving a penile
implant [53]. A hydraulic one to two or three pieces or a
semirigid prosthesis was implanted. None of the patients had
infections or erosions. Thirty-two patients stated they would
undergo surgery again, if necessary or recommend the pros-
thesis; two were dissatisfied, three underwent re-implantation
because of fluid leakage and two complained of penile dis-
comfort. The authors concluded that penile implants had low
morbidity and a high satisfaction rate; complications were
intrinsic to the device and not related to previous radiation
[53]. With the availability of sildenafil, these methods of
therapy are loosing popularity. Sildenafil citrate is a selec-
tive inhibitor of cyclic guanosine monophosphate (cGMP)
specific phosphodiesterase type 5, and hence inhibits the
degradation of cGMP in the cavernosal smooth-muscle cells,
restoring erectile response to sexual stimulation in patients
with ED of different etiologies. The efficacy of sildenafil
after EBRT in open-label studies was reported in up to 90%
of patients [54–57]. However, sildenafil was less effective
in the only double-blind study recently performed [58,59].
Zelefsky et al. [54] reported on 50 patients who presented
with progressive deterioration of sexual functioning, follow-
ing 3DCRT for PC. At a median time of 19 months after
EBRT, treatment with sildenafil resulted in an improvement
in the firmness of erections in 74% of the patients [54]. Kedia
et al. [55] and Weber et al. [56], using the IIEF questionnaire,
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peported a decreased intensity of orgasm, decreased fre-
uency and rigidity of erections, and decreased importance
f sex [18].
.1. Summary
After radiotherapy, other sexual dysfunction than ED have
een reported, such as a decreased libido, ejaculation distur-
ances, and dissatisfaction with sex.
. Therapy of post-radiation erectile dysfunction
If there is still uncertainty about the etiology of post-
adiation ED, what sort of therapy is to be recommended?
rior to the introduction of sildenafil citrate), there were
nly three treatment options: intracavernosal injection (ICI),
acuum devices, and penile implants, all three with or with-
ut concomitant sexual counseling. To our knowledge, only
wo papers were published on therapy of post-radiation ED,
efore sildenafil was introduced.
Pierce et al. reported on eight patients who used an ICI of
hentolamine and papaverine [52]. All patients had erections
ufficient for vaginal penetration with an ICI. One patient
ad a penile haematoma, two reported penile discomfort,
o priapism was encountered. Seven patients continued ICI
or 6–32 months. This study comprised a small sample of
atients, but is the only one reporting on ICI after radiation,
nd demonstrating its efficacy. Dubocq et al. reported on 34
atients who were interviewed about sexual function, satis-eported an improvement of erectile function with sildenafil
n 71 and 77% of the patients, respectively. A prospective
tudy by Valicenti et al. [57] reported on 23 patients, with pre-
BRT data on sexual functioning. The use of a 100 mg dose
f sildenafil citrate, at a median time 12 months post-EBRT,
estored sexual functioning to pre-RT levels in 21 out of
3 patients. Incrocci et al. performed a randomized, double-
lind, placebo-controlled, cross-over trial in 60 patients, who
omplained of ED at a mean time of 39 months post-3DCRT
58]. Sildenafil improved erections significantly as compared
o placebo; 55% of the patients had successful intercourse
ith sildenafil. Ninety percent of the patients needed the 100
g dose, and side effects were mild or moderate. We should
ot forget about patient’s compliance; in a follow-up study of
atients who had previously participated in a sildenafil study,
years after only 24% were till using the drug [59]. The rea-
ons for attrition were lack of efficacy (60%), costs (24%),
nd side effects (16%). Almost one half of the patients were
issatisfied with their sexual life. This indicates that patients
ith a history of cancer treatment and subsequent ED should
e informed on treatment modalities but also followed-up,
nd adequately counseled to improve their sexual life.
.1. Summary
Few data are available on the efficacy of ICI in the treat-
ent of post-radiation ED. Most of the data regard the effi-
acy of sildenafil, which has been reported to be effective in
bout 60% of the patients treated by EBRT in a randomized,
lacebo-controlled trial.
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8. Prevention of post-radiation ED
Prevention is a difficult matter. If one accepts the hypoth-
esis that radiation induces vascular damage, then decreasing
the dose to pelvic vascular structures could decrease ED
rate. Both conventional and conformal radiation techniques
seem to result in the same rates of ED [11]. But, a relation-
ship between radiation field size and sexual function (i.e.
the smaller the field size, the better sexual functioning) has
also been reported [8]. However, prospective studies with
large series of patients, and the use of standardized validated
questionnaires, have to confirm these findings. Conformal
techniques using shaped blocks do not appear to spare the
neuro-vascular bundles as these are always entirely in the
high-dose prostate field. Nevertheless, no reliable data are
available to correlate doses in this region with the occur-
rence of ED after EBRT [60,61]. Furthermore, special radi-
ation beams (such as proton, pion, and neutron) have been
reported to have detrimental effects on potency similar to
those reported for the more commonly used photon beams
[60].
Recently, the IMRT techniques have been introduced.
IMRT is an advanced 3DCRT that uses a computerized
treatment plan optimization with an inverse technique, and
intensity-modulated radiation beams with dynamic multi-
leaf collimator. IMRT was introduced in the treatment of PC
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corpora cavernosa at the crurae of the penis might be impor-
tant in the etiology of ED. Furthermore, nerve injury cannot
be excluded. A multi-factorial etiology has to be considered,
taking into account comorbidity, previous prostate surgery,
drugs, and pre-treatment erectile function. Prevention is a
difficult matter. If one accepts the hypothesis that radiation
induces vascular damage, then decreasing the dose to pelvic
vascular structures could decrease ED rate. The time elapsed
between EBRT and ED evaluation is important as one should
wait at least 18–24 months when ED occurrence reaches a
maximum, and remains stable further on. Too many studies
do not indicate properly when sexual function is assessed.
The definition of (im)potence advocated by the NIH should
always be used, and ED evaluation should be standardized
by using, prospectively, validated questionnaires on quality
of life, and sexual functioning. A better understanding of the
etiology would allow more specific therapeutic modalities.
Finally, sexual counseling is an important aspect. Patients
need to be correctly informed on the anatomy of the prostate,
on the possible sequelae of radiation on their sexual life
and functioning. Being treated for cancer is clearly detri-
mental to patient’s frequency of sexual activity, also in other
than prostate cancer. Sexual activity dropped from two times
weekly to once a month in one study [64]. The stability of
sexual function in husbands and wives of cancer patients sug-
gest that the problem developing after cancer treatment in
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•lready in 1996 resulting in a significantly lower incidence of
ectal toxicity [62]. A comparison of 3DCRT and IMRT plans
f 10 patients with PC showed a significantly lower radiation
ose to the corporal bodies in favor of the IMRT techniques
63]. Because of a strong relationship between radiation dose
n the penile bulb and ED [45], it seems warranted to limit
his dose to prevent post-radiation ED.
.1. Summary
Assuming that the etiology of post-radiation ED is vascu-
ar, a decrease of the radiation dose to the pelvic vasculature
nd penile bodies might result in a decrease of ED. This needs
o be further investigated.
. Conclusion
There are still no conclusive data on EBRT techniques,
eld sizes, energy used, and their specific influence on erec-
ile dysfunction. Both conventional EBRT and conformal
echniques seem to result in the same rates of ED. However,
rospective studies with large series, and the use of standard-
zed validated questionnaires, have to confirm these findings.
onformal techniques using shaped blocks do not appear to
pare the neuro-vascular bundles as these are always entirely
n the high-dose prostate field. No reliable data are available
o correlate doses in this region with the occurrence of ED
fter EBRT. Although arterial damage seems to be the main
ause of ED after EBRT, the radiation dose received by theatients are caused by the emotional and medical impact of
llness rather than by stress in the couple’s relationship [64].
valuating sexual functioning in an oncology population is
ifferent from evaluating it in a healthy population because
f its specific medical, psychological, and social factors. In
usy oncology clinics where outpatient visits must include
ducating patients about their disease, prognosis, and treat-
ent, physicians and nurses often do not have the time of
ssessing quality of life issues [65]. Not only a functional
enis but a functional man, including his partner, has to be the
oal. Thus, sexual desire, satisfaction with sexual life, libido,
nd frequency of intercourse have to be assessed as well.
atients should also be informed about the various effective
reatments for ED which include sildenafil and autoinjection
herapy.
.1. Recommendations
Always define impotence using the definition advocated
by the NIH.
Use internationally validated questionnaires and collect
data on sexual functioning prospectively, because time
since radiotherapy is an important factor.
The incidence of post-radiation ED and of other sexual
dysfunctions is high, thus inform correctly your patients.
There are good treatment options, sildenafil is effective in
about 60% of the patients.
Take the time to discuss sexual matters after radiotherapy,
not only with the patient but with his partner as well.
Cancer patients have the right to enjoy sexual life.
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